ATAI (ATAI) - Stock Analysis
Last updated: Jul 16, 2026
Closed
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strongest short-term catalyst/momentum setup: stock rose about 72% over 21 trading days and about 34% in the last five sessions after Eli Lilly agreed to acquire the company for up to $3.8B, with additional biotech catalysts including EMP-01 Phase 2a results and Russell index inclusion.
Loading chart data...
Idea window: 7/16/2026 – 7/23/2026Sector:
AI Analyst Overview
Loading AI Analyst data...
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 16 | Jul 23 | ATAI | ATAI | Strongest short-term catalyst/momentum setup: stock rose about 72% over 21 trading days and about 34% in the last five sessions after Eli Lilly agreed to acquire the company for up to $3.8B, with additional biotech catalysts including EMP-01 Phase 2a results and Russell index inclusion. | Closed | +0.3% |
| Apr 22 | Apr 29 | ATAI | ATAI | ATAI has a strong catalyst stack for the coming week: positive EMP-01 data, BPL-003 progress toward Phase 3, FDA alignment for pivotal trials, and a 2026-04-20 White House executive order supporting faster psychedelic treatment pathways; the stock rose about 39% over 21 trading days. | Closed | -12.5% |